Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

ceftazidime (Rx)Brand and Other Names:Fortaz, Tazicef, more...Tazidime

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 20mg/mL
  • 40mg/mL

powder for injection

  • 500mg
  • 1g
  • 2g
  • 6g
more...

Bone & Joint Infections

2 g IV q12hr

Gynecologic & Intra-abdominal Infections

2 g IV q8hr for 4-7 days

Pulmonary Infections

Infections caused by Pseudomonas spp in patients with cystic fibrosis who have healthy renal function

30-50 mg/kg IV q8hr; not to exceed 6 g/day  

Meningitis

2 g IV q8hr

Pneumonia

Uncomplicated: 0.5-1 g IV q8hr

Complicated: 2 g IV q8hr

Mild Skin/Skin Structure Infections

0.5-1 g IV or IM q8hr

Urinary Tract Infections

Complicated: 500 mg IV or IM q8-12hr

Uncomplicated: 250 mg IV or IM q12hr

Life-Threatening Infections

Especially in immunocompromised patients

2 g IV q8hr

Dosing Modifications

Renal impairment

  • Modifications based on 1-g dose
  • CrCl 31-50 mL/min: 1 g q12hr
  • CrCl 16-30 mL/min: 1 g q24hr
  • CrCl 6-15 mL/min: 500 mg q24hr
  • CrCl <5 mL/min: 500 mg q48hr

Dosing Considerations

Susceptible organisms

  • Citrobacter spp, Clostridium spp, Enterobacter spp, Escherichia coli, Haemophilus influenzae, Klebsiella spp, Moraxella catarrhalis, Neisseria meningitidis, Proteus mirabilis, Pseudomonas spp, Serratia spp, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes

Dosage Forms & Strengths

injectable solution

  • 20mg/mL
  • 40mg/mL

powder for injection

  • 500mg
  • 1g
  • 2g
  • 6g
more...

Infections Caused by Susceptible Organisms

<1 month: Safety and efficacy not established

1 month-12 years: 30-50 mg/kg IV q8hr; not to exceed 6 g/day (higher end of dosing range reserved for patietns with immunocompromise, meningitis, or cystic fibrosis) 

>12 years: 1-2 g IV q8hr

Dosing Considerations

Use sodium carbonate preparation

Usual dosing range for neonates (per manufacturer)

  • <28 days: 30 mg/kg IV q12hr  

Usual dosing range for neonates (per American Academy of Pediatrics)

  • 7-28 days: 50 mg/kg IV q8hr
  • <7 days, <2 kg: 50 mg/kg IV q12hr
  • <7 days, >2 kg: 50 mg/kg IV q8-12hr
Next

Interactions

Interaction Checker

ceftazidime and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Transient increases in transaminases (3-9%)

            Eosinophilia (<7%)

            Diarrhea (<2%)

            Immune hypersensitivity reaction (2%)

            Phlebitis (<2%)

            Rash (maculopapular or erythematous) (2%)

            Thrombocytosis (2%)

            Injection site pain (1%)

            <1%

            Abdominal pain

            Agranulocytosis

            Angioedema

            Asterixis

            Coma

            Dizziness

            Encephalopathy

            Fever

            Hallucinations

            Increased serum concentrations of bilirubin

            Leukopenia

            Lymphocytosis

            Metallic taste

            Myoclonia

            Nausea or vomiting

            Neuromuscular excitability

            Neutropenia

            Paresthesia

            Photosensitivity

            Pruritus

            Seizures

            Thrombocytopenia

            Transient increases in blood urea nitrogen (BUN) or serum creatinine

            Urticaria

            Previous
            Next

            Warnings

            Contraindications

            Documented hypersensitivity to drug or components

            Cautions

            High serum concentrations may result in serious adverse nervous system effects

            Elevated international normalized ratio (INR) has reported in patients with nutritional deficiency, prolonged treatment, or renal or hepatic disease

            Use with caution in patients with history of seizure disorder (especially in renal impairment, where drug levels may increase significantly)

            Modify dose in renal impairment

            Use with caution in patients with history of penicillin allergy

            Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B

            Lactation: Drug excreted in breast milk; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Third-generation cephalosporin with broad-spectrum gram-negative activity, including Pseudomonas; has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms; arrests bacterial growth by binding to 1 or more penicillin-binding proteins, thereby, in turn, inhibiting final transpeptidation step of peptidoglycan synthesis in bacterial cell-wall synthesis and inhibiting cell-wall biosynthesis

            Absorption

            Peak plasma time: IM, 1 hr

            Distribution

            Widely distributed to body tissues and fluids, including aqueous humor, ascitic and prostatic fluids, and bone; penetrates CSF when meninges are inflamed

            Protein bound: 5-24%

            Metabolism

            Not metabolized

            Elimination

            Half-life: 1-2 hr

            Dialyzable: Hemodialysis, yes; peritoneal dialysis, yes

            Excretion: Urine (80-90% as unchanged drug)

            Previous
            Next

            Administration

            IV Incompatibilities

            Additive: Amikacin, aminophylline, ciprofloxacin, gentamicin, ranitidine

            Y-site: Amiodarone, amphotericin B cholesteryl complex, azithromycin, amsacrine, clarithromycin, cisatracurium(?), doxorubicin liposome, erythromycin lactobionate, fluconazole(?), idarubucin, midazolam, nicardipine (incompatible at ceftazidime 125 mg/mL but compatible at ceftazidime 10 mg/mL), pentamidine, propofol (incompatible at ceftazidime 125 mg/mL but compatible at ceftazidime 40 mg/mL), sagramostim(?), vancomycin(?), warfarin

            IV/IM Administration

            IV

            • Direct injection: Inject over 3-5 minutes directly into vein or through tubing of running compatible infusion solution
            • Infusion: Infuse intermittently over 15-30 minutes

            IM

            • Inject deeply

            Storage

            Store intact vials at room temperature, protected from light

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.